# Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

> **NCT04818372** · PHASE1 · UNKNOWN · sponsor: **Keymed Biosciences Co.Ltd** · enrollment: 87 (estimated)

## Conditions studied

- Multiple Myeloma
- Lymphoma

## Interventions

- **DRUG:** CM313-Dose escalation
- **DRUG:** CM313
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT04818372
- **Lead sponsor:** Keymed Biosciences Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-26
- **Primary completion:** 2023-01
- **Final completion:** 2023-04
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2021-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818372, "Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04818372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*